For formulators developing menopause products, hot-flash support remains important. But menopause is not experienced as a single symptom, and the formulation opportunity should not necessarily be approached that way either.
Women moving through menopause may also be navigating changes involving bone, skin, metabolic health, sleep, mood and cognitive function. This creates a bigger question for product-development teams: Can a menopause formula be built around the broader needs of the woman rather than primarily around hot flashes?
S-equol deserves consideration in that discussion.
Why S-Equol?
S-equol is a biologically active metabolite of daidzein, but not everyone naturally produces it. Providing S-equol directly removes the dependence on an individual's gut microbiota to make that conversion.
More importantly for formulators, there is an established body of human research on S-equol across several areas relevant to menopause.
In a randomized, double-blind study of postmenopausal Japanese women, 10 mg/day of natural S-equol significantly reduced hot-flash frequency and severity compared with placebo and also improved neck and shoulder stiffness.
But the research extends beyond vasomotor symptoms.
A 12-month study in postmenopausal Japanese women who were non-equol producers found that 10 mg/day of natural S-equol reduced a marker of bone resorption and helped slow the loss of whole-body bone mineral density.
Skin has also been studied. In a 12-week trial of postmenopausal Japanese women, natural S-equol supplementation significantly reduced crow's-feet wrinkle area, with the higher studied dose also reducing wrinkle depth.
Research involving overweight and obese Japanese adults has additionally reported changes in LDL cholesterol, HbA1c and arterial stiffness. This was not a menopause study, but it adds another area of scientific interest as researchers continue investigating the potential applications of S-equol.
For formulators, the significance is the breadth of the opportunity. S-equol does not have to be evaluated solely as another ingredient for hot-flash support. It can be
considered within the development of more comprehensive menopause and women's-health formulations.
If You Want S-Equol, Which S-Equol?
That question brings the discussion to EquoYouth® from Bonerge Lifescience.
For formulators, choosing S-equol is only the first decision. The source of that S-equol—and the specifications, manufacturing process and sourcing options behind it—can matter just as much when moving from scientific rationale to a commercial formulation.
EquoYouth® is produced using Bonerge's proprietary bio-fermentation technology, yielding S-equol with greater than 99% S-configuration purity—the same form produced naturally in the human body. Rather than simply specifying “S-equol” as a generic raw material, formulators have a highly defined branded ingredient with a controlled specification.
EquoYouth® is available in two grades with the same specification, differing in the source of the daidzein used as the fermentation starting material. Grade A starts with plant-derived daidzein from a proprietary non-soy botanical source, while Grade B is fermented from synthetic daidzein and carries Self-Affirmed GRAS status. Both grades are soy-free.
That combination creates a compelling distinction when evaluating commercial S-equol sources. EquoYouth® brings together >99% S-configuration purity, proprietary fermentation technology, sourcing flexibility, soy-free positioning and a developing ingredient-specific clinical program. For formulators, the evaluation therefore becomes more than simply “Do I want S-equol in this formula?” It becomes “Which S-equol do I want to build the formula around?”
Building the EquoYouth® Evidence
Bonerge is now taking the next important step: building clinical evidence specifically around EquoYouth®.
Building on the established body of S-equol research, Bonerge initiated its first EquoYouth® human pilot study in August 2026, evaluating menopausal symptom improvement and safety in Chinese women. The study represents the beginning of Bonerge's EquoYouth®-specific clinical program and is designed to help inform a larger randomized controlled trial.
Bonerge ultimately sees opportunities for S-equol extending from reproductive-age women's health through perimenopause and longer-term healthy aging. Those remain areas of formulation opportunity rather than established EquoYouth® benefits.
For product-development teams, the opportunity may be bigger than simply adding EquoYouth® to an existing menopause formula. As women's health formulations continue to move beyond single-symptom support, EquoYouth® deserves consideration as a potential hero ingredient around which a more comprehensive women's-health formula can be built.
Much as Shatavari has gained renewed attention as brands look beyond conventional menopause ingredients, S-equol represents another emerging formulation opportunity backed by an established body of human research. EquoYouth® gives formulators a differentiated branded S-equol to evaluate as they consider where women's-health formulation is heading next.
Evaluate EquoYouth® on NXT Ingredients®.

